Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2022

View Archived Issues

Novel Fanconi anemia xenograft murine model to test immunotherapy

Allorion Therapeutics presents TYK2 inhibitor ARTS-011 for the treatment of inflammatory disease

Autoantibody-induced murine dry eye disease model mimics human disease

Novel Nr1h3-/- mouse model exhibits AMD-like pathology

MFAP4 as a novel target in choroidal neovascularization

Across body parts, "parts list" gives insights into the lives of a cell

Chinese investigators patent new HIF inhibitors

Medivir and Rheos Medicines divulge new MALT1 inhibitors

U.S. researchers describe new PROTACs for cancer

Johns Hopkins University synthesizes MAP3K12/13 inhibitors

Chinese researchers disclose new CDK9 inhibitors

Kymera presents preclinical data on STAT3 degrader KTX-115

VERVE-101 shows durable editing of PCSK9 gene; GalNAc-LNPs improve delivery of base editors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...